Treatment of Non-Seminomatous Germ Cell Tumours
Author Information
Author(s): J. Graham, M. Harding, L. Mill, D.J. Kerr, E. Rankin, K.C. Calman, S.B. Kaye
Primary Institution: Cancer Research Campaign Department of Medical Oncology, Western Infirmary, Glasgow, UK
Hypothesis
The study aims to review the presentation and management of patients with non-seminomatous germ cell tumours over a five-year period.
Conclusion
The majority of patients with metastatic non-seminomatous germ cell tumours are curable with chemotherapy, although those with very large volume metastases or extragonadal tumours may require alternative treatments.
Supporting Evidence
- 91% of patients with testicular tumours had a 2-year survival rate.
- 25% of patients with extragonadal tumours had a 2-year survival rate.
- Patients with very large volume metastatic disease had a significantly worse survival rate of 57%.
Takeaway
Most patients with a certain type of cancer can be treated successfully with medicine, but some need different treatments if their cancer is very advanced.
Methodology
The study analyzed 122 consecutive patients treated at a regional referral center, focusing on their treatment outcomes and survival rates.
Limitations
The study may not account for long-term follow-up beyond two years, and the sample size for certain analyses was insufficient.
Participant Demographics
Patients were primarily from the West of Scotland, with a focus on those presenting with non-seminomatous germ cell tumours.
Statistical Information
P-Value
p<0.005
Statistical Significance
p<0.005
Want to read the original?
Access the complete publication on the publisher's website